Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Mar 19

PMID 32183335

Citations 10

Authors

Maxime Jullien

Patricia Gomez-Bougie

David Chiron

Cyrille Touzeau

Affiliations

Soon will be listed here.

Abstract

Apoptosis is a highly conserved mechanism enabling the removal of unwanted cells. Mitochondrial apoptosis is governed by the B-cell lymphoma (BCL-2) family, including anti-apoptotic and pro-apoptotic proteins. Apoptosis evasion by dysregulation of anti-apoptotic BCL-2 members (BCL-2, MCL-1, BCL-X) is a common hallmark in cancers. To divert this dysregulation into vulnerability, researchers have developed BH3 mimetics, which are small molecules that restore effective apoptosis in neoplastic cells by interfering with anti-apoptotic proteins. Among them, venetoclax is a potent and selective BCL-2 inhibitor, which has demonstrated the strongest clinical activity in mature B-cell malignancies, including chronic lymphoid leukemia, mantle-cell lymphoma, and multiple myeloma. Nevertheless, mechanisms of primary and acquired resistance have been recently described and several features such as cytogenetic abnormalities, BCL-2 family expression, and ex vivo drug testing have to be considered for predicting sensitivity to BH3 mimetics and helping in the identification of patients able to respond. The medical need to overcome resistance to BH3 mimetics supports the evaluation of innovative combination strategies. Novel agents including MCL-1 targeting BH3 mimetics are currently evaluated and may represent new therapeutic options in the field. The present review summarizes the current knowledge regarding venetoclax and other BH3 mimetics for the treatment of mature B-cell malignancies.

Citing Articles

CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth.

Lin Y, Zhao Y, Chen M, Li Z, Liu Q, Chen J BMC Cancer. 2023; 23(1):479.

PMID: 37237269 PMC: 10224611. DOI: 10.1186/s12885-023-10974-4.

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.

Thus Y, Eldering E, Kater A, Spaargaren M Leukemia. 2022; 36(9):2165-2176.

PMID: 35725771 PMC: 9418002. DOI: 10.1038/s41375-022-01627-9.

DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung Cancer.

Liu M, Xu C, Qin X, Liu W, Li D, Jia H Front Oncol. 2022; 12:873649.

PMID: 35646704 PMC: 9137409. DOI: 10.3389/fonc.2022.873649.

Intrinsically Connected: Therapeutically Targeting the Cathepsin Proteases and the Bcl-2 Family of Protein Substrates as Co-regulators of Apoptosis.

Soond S, Kozhevnikova M, Savvateeva L, Townsend P, Zamyatnin Jr A Int J Mol Sci. 2021; 22(9).

PMID: 33925117 PMC: 8124540. DOI: 10.3390/ijms22094669.

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

Premkumar V, Lentzsch S, Pan S, Bhutani D, Richter J, Jagannath S Blood Cancer J. 2021; 11(1):10.

PMID: 33431806 PMC: 7801694. DOI: 10.1038/s41408-020-00397-w.

References

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

Blunt M, Koehrer S, Dobson R, Larrayoz M, Wilmore S, Hayman A . The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2016; 23(9):2313-2324. PMC: 5417366. DOI: 10.1158/1078-0432.CCR-16-1662. View

Guieze R, Liu V, Rosebrock D, Jourdain A, Hernandez-Sanchez M, Zurita A . Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019; 36(4):369-384.e13. PMC: 6801112. DOI: 10.1016/j.ccell.2019.08.005. View

Scott D, Gascoyne R . The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014; 14(8):517-34. DOI: 10.1038/nrc3774. View

Smith V, Dietz A, Henz K, Bruecher D, Jackson R, Kowald L . Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. Haematologica. 2019; 105(8):2150-2163. PMC: 7395267. DOI: 10.3324/haematol.2019.220525. View

Davids M, Deng J, Wiestner A, Lannutti B, Wang L, Wu C . Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012; 120(17):3501-9. PMC: 3482860. DOI: 10.1182/blood-2012-02-414060. View

Cang S, Iragavarapu C, Savooji J, Song Y, Liu D . ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol. 2015; 8:129. PMC: 4654800. DOI: 10.1186/s13045-015-0224-3. View

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G . Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019; 380(22):2095-2103. PMC: 11827445. DOI: 10.1056/NEJMoa1900574. View

Tracey L, Perez-Rosado A, Artiga M, Camacho F, Rodriguez A, Martinez N . Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol. 2005; 206(2):123-34. DOI: 10.1002/path.1768. View

10.

Montero J, Sarosiek K, DeAngelo J, Maertens O, Ryan J, Ercan D . Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015; 160(5):977-989. PMC: 4391197. DOI: 10.1016/j.cell.2015.01.042. View

11.

Chiron D, Dousset C, Brosseau C, Touzeau C, Maiga S, Moreau P . Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015; 6(11):8750-9. PMC: 4496181. DOI: 10.18632/oncotarget.3275. View

12.

Moreau P, Chanan-Khan A, Roberts A, Agarwal A, Facon T, Kumar S . Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017; 130(22):2392-2400. DOI: 10.1182/blood-2017-06-788323. View

13.

Chonghaile T, Sarosiek K, Vo T, Ryan J, Tammareddi A, Gaizo Moore V . Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011; 334(6059):1129-33. PMC: 3280949. DOI: 10.1126/science.1206727. View

14.

Hockenbery D, Zutter M, Hickey W, Nahm M, Korsmeyer S . BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A. 1991; 88(16):6961-5. PMC: 52213. DOI: 10.1073/pnas.88.16.6961. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Seymour J, Kipps T, Eichhorst B, Hillmen P, DRozario J, Assouline S . Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018; 378(12):1107-1120. DOI: 10.1056/NEJMoa1713976. View

17.

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

18.

Tam C, Anderson M, Pott C, Agarwal R, Handunnetti S, Hicks R . Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med. 2018; 378(13):1211-1223. DOI: 10.1056/NEJMoa1715519. View

19.

Chen S, Chang B, Chang S, Tong T, Ham S, Sherry B . BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2015; 30(4):833-43. PMC: 4832074. DOI: 10.1038/leu.2015.316. View

20.

Kumar S, Kaufman J, Gasparetto C, Mikhael J, Vij R, Pegourie B . Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017; 130(22):2401-2409. DOI: 10.1182/blood-2017-06-788786. View